Details
- ●Modalities: proteins, enzymes, antibodies
- ●Therapeutic areas: Undisclosed
- ●Key targets:
- ●Indications: Undisclosed
- ●Funding: $24M
Key considerations
- ●AI tools in use: Cradle Platform (SaaS)
- ●$24M Series A (2023)
- ●Multi-biotech customer base (Johnson Matthey, Constructive Bio, others disclosed)
- ●Swiss/Dutch footprint
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)